Concepedia

Inga Galuba

IG

Statistics

Publications

6

Citations

349

H-Index

6

Active since

2002

Affiliations

Novartis (Switzerland)(Current)

Novartis Institutes for BioMedical Research

Inga Galuba is an author at Novartis (Switzerland) specializing in drug discovery, drug design, and ligand binding.

Publications per year

2002–2023

6

Publications

6

Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4

Robin A. Fairhurst, Thomas Knoepfel, Nicole Buschmann et al. · Journal of Medicinal Chemistry · 2020 · 113 citations · Full text

, , +15

Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor

Alexei S. Karpov, Payman Amiri, Cornelia Bellamacina et al. · ACS Medicinal Chemistry Letters · 2015 · 109 citations · Full text

, , +16

2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4

Thomas Knoepfel, Pascal Furet, Robert Mah et al. · ACS Medicinal Chemistry Letters · 2018 · 43 citations · Full text

, , +17

Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region

Robin A. Fairhurst, Thomas Knoepfel, Catherine Leblanc et al. · MedChemComm · 2017 · 41 citations · Full text

, , +17

Association of Time to Recurrence With Thymidylate Synthase and Dihydropyrimidine Dehydrogenase mRNA Expression in Stage II and III Colorectal Cancer

Marko Kornmann, Karl H. Link, Inga Galuba et al. · Journal of Gastrointestinal Surgery · 2002 · 33 citations

, , +13

1–5 of 6